PDCD1 and neoplasm: Indeed, monoclonal antibodies (mAb)s targeting PD-1, PD-L1, and CTLA-4 immune checkpoints leading to increased anti-tumor response due to increased T-cell activity and proliferation, have received regulatory approval across a wide range of tumors, including NSCLC (26).